Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer

Background: Bisphosphonate (BP) treatment to prevent bone loss in breast cancer patients is already well established. However, data on the association between oral BP exposure before cancer diagnosis and disease outcomes in patients with early breast cancer are still scarce. Limited information is a...

Full description

Bibliographic Details
Main Authors: Vanessa Rouach, Inbal Goldshtein, Ido Wolf, Raphael Catane, Gabriel Chodick, Amit Iton, Naftali Stern, Daniel Cohen
Format: Article
Language:English
Published: Elsevier 2018-09-01
Series:Journal of Bone Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137418300496